secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-05-15T11:43:39+00:00
Accession:  0001790340-26-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1
--------------------------------------------------------------------------------

- Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.
- Cash, equivalents and marketable securities $198.6M (Dec 31, 2025: $217.0M); runway into 2029.
- R&D expenses $10.6M (down from $11.5M YoY); G&A expenses $4.7M (up from $4.0M).
- Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer now recruiting; first patient dosing mid-2026.
- Updated survival data from Phase 2a cohort (55 patients) to be presented in oral session at ASCO June 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/0001790340-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/imrx-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer